Mepolizumab, an experimental monoclonal antibody against interleukin, appears to be effective and well tolerated as a treatment for reducing the risk of asthma exacerbations in patients with severe eosinophilis asthma. A clinical trial conducted in 13 countries showed that patients receiving three different doses of mepolizumab had reductions in exacerbation rates that were considered clinically significant.
Abstract: Lancet, August 18, 2012 (online).
